Low levels of antiretroviral-resistant HIV infection in a routine clinic in cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment

Clinical Infectious Diseases

Volumn 48, Issue 9, 2009, Pages 1318-1322

  Kouanfack, Charles ^a   Montavon, Celine ^b   Laurent, Christian ^b   Aghokeng, Avelin ^a   Kenfack, Alain ^a   Bourgeois, Anke ^c   Koulla Shiro, Sinata ^a   Mpoudi Ngole, Eitel ^a   Peeters, Martine ^b   Delaporte, Eric ^b,c  

^a Institut de Recherche pour le Developpement Cameroon   (Cameroon)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CAMEROON; CROSS-SECTIONAL STUDY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; VIROLOGY; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; ANTIVIRAL RESISTANCE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CAMEROON; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GUIDELINE ADHERENCE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 65549128209     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597779     Document Type: Article

References (12)

1. World Health Organization (WHO), Joint United Nations Program on HIV/AIDS, United Nations Children's Fund. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector : progress report. Geneva, Switzerland: WHO, 2008. Available at: http://www.who.int/hiv/. Accessed 24 March 2009.
2. World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, Switzerland: WHO, 2006. Available at: http: //www.who.int/hiv. Accessed 24 March 2009.
3. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10.
4. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-11.
5. Vergne L, Bourgeois A, Mpoudi-Ngole E, et al. Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02AG variant and disease stage. Virology 2003;310:254-66.
6. Rouet F, Chaix ML, Nerrienet E, et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Na- tionale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr 2007; 45:380-8.
7. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther 2006; 11:575-9.
8. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22 :4673-80.
9. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan africa: a systematic review. PLoS Med 2007;4: e298.
10. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV-1-infected patients whose initial regimen of a fixed dose combinatiion of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-52.
11. Hosseinipour M, van Oosterhout JJ, Weigel R, et al. Resistance profile of patients failing first-line ART in Malawi when using clinical and immunologic monitoring [abstract TUAB0105]. In: Program and abstracts of the XVII International AIDS Conference (Mexico). 2008.
12. Bisson GP, Gross R, Bellamy S, et al. Adherence monitoring pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on Antiretroviral therapy. PLoS Med 2008; 5:e109.